> top > docs > PMC:7306567 > spans > 33044-38353 > annotations

PMC:7306567 / 33044-38353 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
340 2797-2818 Disease denotes Stepstone Pharma GmbH
341 5246-5264 Disease denotes FL van de Veerdonk MESH:C536528

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T164 71-74 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T165 256-259 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T166 320-323 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T167 360-363 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T168 387-390 Disease denotes BMS http://purl.obolibrary.org/obo/MONDO_0006687
T169 425-428 Disease denotes BMS http://purl.obolibrary.org/obo/MONDO_0006687
T170 438-441 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T171 465-467 Disease denotes he http://purl.obolibrary.org/obo/MONDO_0017319
T172 497-500 Disease denotes BMS http://purl.obolibrary.org/obo/MONDO_0006687
T173 510-513 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T174 962-965 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T175 1278-1281 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T176 1427-1430 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T177 1460-1463 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T178 1603-1606 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T179 2559-2562 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T180 2851-2854 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T181 3025-3028 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T182 3099-3102 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T183 3133-3136 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T184 3251-3254 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T185 3472-3475 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T186 3534-3537 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T187 3659-3662 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T188 4715-4718 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T189 4927-4930 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T190 5166-5169 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T191 5213-5216 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T218 275-278 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T219 562-563 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T220 680-683 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T221 910-913 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T222 1085-1088 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T223 1773-1776 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T224 2223-2226 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T225 2397-2399 http://www.ebi.ac.uk/efo/EFO_0000265 denotes Da
T226 2910-2912 http://purl.obolibrary.org/obo/CLO_0001980 denotes BJ
T227 2922-2925 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T228 2931-2932 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T229 3326-3329 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T230 3371-3374 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T231 3438-3441 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T232 3489-3492 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T233 3614-3617 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T234 3696-3697 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T235 4028-4030 http://purl.obolibrary.org/obo/CLO_0007706 denotes MH
T236 4038-4041 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T237 4476-4479 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T238 4652-4655 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T239 4723-4726 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T240 4848-4851 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T241 4963-4966 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T242 5095-5096 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T243 5246-5248 http://purl.obolibrary.org/obo/CLO_0003358 denotes FL
T244 5265-5268 http://purl.obolibrary.org/obo/CLO_0051582 denotes has

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T233 22-24 Chemical denotes PE http://purl.obolibrary.org/obo/CHEBI_16038|http://purl.obolibrary.org/obo/CHEBI_17553|http://purl.obolibrary.org/obo/CHEBI_74762
T236 1631-1633 Chemical denotes GE http://purl.obolibrary.org/obo/CHEBI_73801
T237 2109-2111 Chemical denotes OA http://purl.obolibrary.org/obo/CHEBI_138856
T238 2761-2763 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T239 4028-4030 Chemical denotes MH http://purl.obolibrary.org/obo/CHEBI_74703
T240 4269-4271 Chemical denotes TF http://purl.obolibrary.org/obo/CHEBI_74862
T241 4466-4468 Chemical denotes TR http://purl.obolibrary.org/obo/CHEBI_74825
T242 5246-5248 Chemical denotes FL http://purl.obolibrary.org/obo/CHEBI_91150

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T245 0-21 Sentence denotes Conflicts of interest
T246 22-164 Sentence denotes PE Verweij reported grants from Gilead Sciences, MSD, Pfizer and F2G, and non-financial support from OLM and IMMY, outside the submitted work.
T247 165-536 Sentence denotes BJA Rijnders was the investigator for studies supported by Gilead Sciences, Janssen-Cilag, MSD, Pfizer, ViiV; has received research grants from Gilead and MSD; was an invited speaker for Gilead, MSD, Pfizer, Jansen-Cilag, BMS; and an advisory board member for BMS, Abbvie, MSD, Gilead, Jansen-Cilag; he received travel support from BMS, Abbvie, MSD, Gilead, Jansen-Cilag.
T248 537-814 Sentence denotes RJM Brüggemann served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc.
T249 815-899 Sentence denotes All contracts were through Radboudumc, and all payments were invoiced by Radboudumc.
T250 900-986 Sentence denotes E Azoulay has received fees for lectures from Pfizer, Gilead, MSD, Alexion and Baxter.
T251 987-1073 Sentence denotes His institution received research support from Fisher&Payckle, Jazz pharma and Gilead.
T252 1074-1377 Sentence denotes M Bassetti has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, AstraZeneca, Basilea, Bayer, BioMèrieux, Cidara, Correvio, Cubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Shionogi, Tetraphase, Thermo Fisher and The Medicine Company.
T253 1378-1524 Sentence denotes S Blot received research funding from Pfizer and MSD, travel support from Pfizer, MSD and Gilead, and is an invited speaker for Pfizer and Gilead.
T254 1525-1728 Sentence denotes T Calandra reported advisory board membership from Astellas, Basilea, Cidara, MSD, Sobi, ThermoFisher and GE Healthcare and data monitoring board membership from Novartis, all outside the submitted work.
T255 1729-1762 Sentence denotes Fees are paid to its institution.
T256 1763-2108 Sentence denotes CJ Clancy has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this project, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Qpex and Needham & Company, and spoken at symposia sponsored by Merck and T2Biosystems.
T257 2109-2670 Sentence denotes OA Cornely is supported by the German Federal Ministry of Research and Education and the European Commission, and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Merck/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical.
T258 2671-2715 Sentence denotes T Chiller reported no conflicts of interest.
T259 2716-2760 Sentence denotes P Depuydt reported no conflicts of interest.
T260 2761-2862 Sentence denotes DR Giacobbe reported honoraria from Stepstone Pharma GmbH and an unconditional grant from MSD Italia.
T261 2863-2909 Sentence denotes NAF Janssen reported no conflicts of interest.
T262 2910-2984 Sentence denotes BJ Kullberg has been a scientific advisor for Amplyx, Cidara and Scynexis.
T263 2985-3152 Sentence denotes K Lagrou received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, travel support from Pfizer and MSD and speaker fees from Gilead, MSD, FUJIFILM WAKO.
T264 3153-3316 Sentence denotes C Lass-Florl received research funding from Pfizer, Gilead and Egger, travel support from Pfizer, MSD, and Gilead, and is an invited speaker for Pfizer and Gilead.
T265 3317-3423 Sentence denotes RE Lewis has received research support from Merck and has served as an invited speaker for Gilead, Cidara.
T266 3424-3600 Sentence denotes P Wei-Lun Liu has received research grants from MSD, Pfizer, and has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is an advisor to Pfizer, Gilead.
T267 3601-3738 Sentence denotes O Lortholary has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is a consultant for Gilead, Novartis and F2G.
T268 3739-3975 Sentence denotes J Maertens reported personal fees and non-financial support from Basilea Pharmaceuticals, Bio-Rad Laboratories, Cidara, F2G Ltd., Gilead Sciences, Merck, Astellas, Scynexis, and Pfizer Inc. and grants from Gilead Sciences, IMMY and OLM.
T269 3976-4027 Sentence denotes I Martin-Loeches reported no conflicts of interest.
T270 4028-4268 Sentence denotes MH Nguyen has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this study and served on advisory boards for Astellas, Merck, the Medicines Company, Scynexis and Shionogi.
T271 4269-4465 Sentence denotes TF Patterson reported grants from Cidara to UT Health San Antonio; personal fees from Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga, Toyama and United Medical outside the submitted work.
T272 4466-4639 Sentence denotes TR Rogers has received grants from Gilead Sciences, lecture honoraria from Gilead Sciences and Pfizer Healthcare Ireland, and advisory board membership with Menarini Pharma.
T273 4640-4753 Sentence denotes JA Schouten has received unrestricted educational and research grants from MSD and has been an advisor to Pfizer.
T274 4754-4838 Sentence denotes All contracts were through Radboudumc, and all payments were invoiced by Radboudumc.
T275 4839-4958 Sentence denotes I Spriet has received unrestricted research grants, speaker fees and travel grants from MSD, Pfizer, Gilead and Cidara.
T276 4959-5007 Sentence denotes She has served in the advisory board for Cidara.
T277 5008-5117 Sentence denotes L Vanderbeke is supported by the Flanders Research Foundation (FWO Vlaanderen) through a doctoral fellowship.
T278 5118-5245 Sentence denotes J Wauters reported grants from Gilead Sciences, MSD and Pfizer, and non-financial support from MSD, outside the submitted work.
T279 5246-5309 Sentence denotes FL van de Veerdonk has served as an invited speaker for Gilead.